Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
HSPH1
REST API REST API
Homo sapiens
HSPH1 is differentially expressed in 332 experiments: 126 organism parts: bone marrow, amygdala, ... (124 more);, 217 disease states: normal, prostate carcinoma, ... (215 more);, 102 cell types 418 cell lines 50 compound treatments and 75 other conditions.
Synonyms HSP105A, HSP105B, KIAA0201, NY-CO-25
Orthologs Hsph1 (Mus musculus)   SSE2 (Saccharomyces cerevisiae)   Hsph1 (Rattus norvegicus)   SSE1 (Saccharomyces cerevisiae)   F6Y4H4_CIOIN (Ciona intestinalis)   HS105_BOVIN (Bos taurus)   HSPH1 (Danio rerio)   E1BT08_CHICK (Gallus gallus)   Hsc70Cb (Drosophila melanogaster)   hsph1 (Xenopus laevis)   HSPH1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term protein binding, chaperone mediated protein folding requiring cofactor, cytoplasm, response to stress, extracellular region, cell morphogenesis, response to unfolded protein, alpha-tubulin binding, ATP binding, microtubule, nucleotide binding, positive regulation of NK T cell activation, positive regulation of MHC class I biosynthetic process
InterPro Term Hsp70, Hsp_70, MreB_Mrl
UniProt Accession Q92598, Q5TBM3, B4DYH1, B4DY72, E7EUG1, F2Z3D7
Search EB-eye ENSG00000120694
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-1577, E-MEXP-433, ... (34 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-18005, ... (40 experiments)

Factor Value U/D Experiments
SW480
3
E-MEXP-1014, E-GEOD-18005, E-MTAB-37
PC3
2
E-GEOD-14464, E-MEXP-2034
AGS
2
E-MTAB-37, E-GEOD-15460
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
HL-60
2
E-GEOD-5258, E-GEOD-24147
cal 27
1
E-MTAB-62
412 more value(s).


Cell type

studied in E-GEOD-22529, E-GEOD-20193, E-GEOD-500, E-GEOD-3920, E-GEOD-360, ... (46 experiments)

Factor Value U/D Experiments
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
dendritic cell
1
E-GEOD-360
macrophage
1
E-GEOD-360
endothelial cells and pericytes
1
E-MEXP-1251
purified CLL B cells from peripheral blood
1
E-GEOD-22529
activated natural killer cell (supplemented for IL2 for 2 hours)
1
E-TABM-702
96 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-MTAB-62, E-MTAB-680, ... (59 experiments)

Factor Value U/D Experiments
colon carcinoma
3
E-MTAB-57, E-MTAB-62, E-GEOD-3726
lung adenocarcinoma
3
E-MTAB-37, E-MEXP-231, E-MTAB-62
astrocytoma
2
E-MTAB-37, E-GEOD-4290
colorectal carcinoma
2
E-GEOD-23878, E-MTAB-37
lung carcinoma
2
E-MTAB-37, E-GEOD-6014
multiple myeloma
2
E-MTAB-62, E-GEOD-6691
211 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-TABM-782, E-GEOD-3720, E-GEOD-5824, ... (34 experiments)

Factor Value U/D Experiments
none
6
7
E-TABM-782, E-GEOD-20719, E-MEXP-1601, E-GEOD-7400, E-MEXP-1230, ... (13 experiments)
NaOH
1
E-MEXP-2590
sapphyrin PCI-2051
1
E-GEOD-6400
vanadium pentoxide
1
E-GEOD-5339
unknown
1
E-GEOD-7307
anti-CD3 antibody (clone:OKT3)
1
E-MEXP-1601
44 more value(s).


Age at diagnosis

studied in E-GEOD-21653

Factor Value U/D Experiments
36
2
1
E-GEOD-21653


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd4
studied in E-GEOD-22601

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-GEOD-2171, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-17189, E-GEOD-6710, E-GEOD-19348, ... (11 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-2171, E-GEOD-6532

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-GEOD-20033, E-MEXP-2359, E-GEOD-6236, E-GEOD-4667, ... (8 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-1323, E-GEOD-19743, E-GEOD-3325, E-TABM-147, ... (6 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720, E-GEOD-4086

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-MTAB-73, E-GEOD-4025, E-MEXP-1482, E-GEOD-17385, E-GEOD-20847, ... (7 experiments)

Genotype
studied in E-MEXP-149, E-GEOD-17476, E-GEOD-22593, E-TABM-321, E-GEOD-18005, ... (8 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-GEOD-20540, E-GEOD-22278, E-GEOD-10315, ... (16 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-20559, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-MEXP-2069, E-GEOD-1926, ... (32 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-MEXP-561, E-GEOD-17400, E-GEOD-6802 ... (5 experiments)

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-7819, E-GEOD-19703, E-GEOD-1309, E-GEOD-22152, E-GEOD-21750, ... (7 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-1676, E-MEXP-101, E-MEXP-548, E-GEOD-3697, E-MEXP-1857, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-MEXP-70, E-GEOD-18995

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-19069, E-GEOD-7307

Sirna
studied in E-GEOD-21575, E-GEOD-21574

Stimulation
studied in E-GEOD-4883, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Stimulus or stress
studied in E-GEOD-7538

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-4922, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Tissue
studied in E-GEOD-30573

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-GEOD-19246, E-GEOD-13818, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4271, E-GEOD-22541, E-GEOD-4922

Processing time: 0.453 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM